Joseph Cahill, MD
Neurology · Pensacola, FLNPI 1427346766
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $487 and has fallen 80.5% since, to $95 in 2025. That places this record below the midpoint for neurology clinicians in FL, where the typical reported total is $1,698.
Across 63 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$336
- AstraZeneca$172
- AbbVie$163
- Eisai Inc.$160
- Ceribell, Inc.$152
- Pfizer$117
- plus $599 from 16 others
Across 12 payments — averaging $23,974 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$146K
- Eli Lilly$98K
- Sage Therapeutics, LLC$19K
- AbbVie$14K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$11K
What the payments were for
- Speaking & faculty fees$161%
- Food & beverage$1,68299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $336 |
| AstraZeneca | 7 | $172 |
| AbbVie(2 entities) | 9 | $163 |
| Eisai Inc. | 4 | $160 |
| Ceribell, Inc. | 1 | $152 |
| Pfizer | 6 | $117 |
| Lilly USA, LLC | 5 | $98 |
| UCB, Inc. | 1 | $95 |
| Amgen(2 entities) | 4 | $72 |
| Lundbeck LLC | 2 | $51 |
| Neos Therapeutics, LP | 2 | $50 |
| Biogen | 3 | $49 |
| GE HealthCare | 1 | $30 |
| Argenx US, Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- POCKET EEG DEVICE$152
- AJOVY$109
- AUSTEDO$103
How this compares
$1,698 in reported general payments places this provider in the 50th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 16 | $3,532 |
| Quetiapine Fumarate | 79 | $1,298 |
| Levetiracetam | 19 | $1,074 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 28 | $891 |
| Celecoxib | 33 | $691 |
| Divalproex Sodium | 14 | $582 |
| Pregabalin | 18 | $514 |
| Propranolol Hcl | 11 | $477 |
| Gabapentin | 29 | $475 |
| Donepezil Hcl | 23 | $207 |
| Atorvastatin Calcium | 15 | $183 |
| Topiramate | 18 | $92 |
Paid to pharmacies, not to this prescriber.
Other neurology in Pensacola
- David BearPensacola$513K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.